CLDF Title
Home | Contact Us | Bookmark
About CLDF Centers of Educational Expertise  
Webcasts Slide Library Abstract Library Conference Highlights
Reuters Health Information (2006-05-01): Human Genome says hepatitis C drug worked in combo

Drug & Device Development

Human Genome says hepatitis C drug worked in combo

Last Updated: 2006-05-01 9:13:52 -0400 (Reuters Health)

NEW YORK (Reuters) - Offering potential for the treatment of patients with hepatitis C, Albuferon(tm) may require less frequent dosing and fewer side effects than pegylated interferons,

Human Genome Sciences Inc. on Monday said interim results of a mid-stage trial of Albuferon, its experimental drug for hepatitis C, showed it succeeded at lowering the amount of the virus in the blood when taken in combination with another drug, ribavirin.

The company said the trial, which enrolled 115 patients, showed that the drug was also safe and well-tolerated.

The trial subjects, who had chronic hepatitis C, failed to respond to previous drug regimins, the company said.

Slide Library
Abstract Library
Slide Library
Abstract Library
Slide Library
Abstract Library
Slide Library
Abstract Library
CLDF Follow Us
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
Centers of
Educational Expertise
Regional Map
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2015 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.